CN1177592C - Myocarditis treating medicine - Google Patents
Myocarditis treating medicine Download PDFInfo
- Publication number
- CN1177592C CN1177592C CNB021252882A CN02125288A CN1177592C CN 1177592 C CN1177592 C CN 1177592C CN B021252882 A CNB021252882 A CN B021252882A CN 02125288 A CN02125288 A CN 02125288A CN 1177592 C CN1177592 C CN 1177592C
- Authority
- CN
- China
- Prior art keywords
- medicine
- myocarditis
- obvious
- total saponin
- radix hedysari
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to medicine for curing cardiac muscles, which is characterized in that total saponin is extracted from traditional Chinese medicine sweetvetch root. Oral liquid or intravenous injection liquid is prepared from sterile physiological salt water or a phosphoric acid buffer solution. The medicine is proved by animal experiments that the medicine has obvious functions for resisting myocarditis viruses and inhibiting the pathological changes of Coxsackie B3 virus cells. Compared with western medicine 'ribavirin', the medicine has an obvious protecting function for myocarditis, has no toxic or side effect and has obvious curative effect for curing the myocarditis.
Description
Technical field
The present invention relates to treat myocarditic medicine, the Chinese medicine Radix Hedysari extract of more specifically saying so is as the myocarditic medicine of treatment.
Background technology
Viral myocarditis is to cause one of neonate and death of child disease with high, and its pathogenic process is that virus causes myocardium inflammation.Most of patients causes the chronic myocarditis process, finally causes cardiomyopathy.Even in medical more developed country, cardiomyopathy patient's five-year survival rate is also very low, the main cause that causes this process is that the myocarditis morbidity is left in the basket in early days easily, and after the generation of the cardiomyopathy in the lag phase chronic myocarditis process, lack effective Drug therapy again, cause myocarditis treatment aspect not have substantive progress for many years, become one of serious harm child and the able-bodied disease of teenager.The main Western medicine of myocarditis treatment is divided into two classes clinically: a class is myocardial nutrition medicine (Energy mixture); Another kind of is antiviral agents (as virazole).Energy mixture poor effect, and the antiviral agents side effect is bigger, all undesirable, what have stops using, domestic granted number Chinese medicine quantity seldom, curative effect is also undesirable, and the medicine that is used for child patient is still for blank.
Summary of the invention
The objective of the invention is to overcome the prior art deficiency, a kind of medicine with total Saponin of Chinese medicine Radix Hedysari extract of obvious anti-myocarditis toxic action as the treatment myocarditis is provided.
Medicine of the present invention is that the total Saponin of Radix Hedysari extract is mixed with oral liquid or the intravenous injection liquid formulation that concentration is 0.08-0.24mg/L with physiological saline solution or phosphate buffer (PBS).
The extraction process of total Saponin of the present invention is that known method (sees " northwest pharmaceutical journal " for details, calendar year 2001, the 16th volume, 4 phases, the 157th page), its main process: the Radix Hedysari drug material is pulverized, is soaked with methanol, filter methanol filtrate, methanol is reclaimed in distillation, get extractum, use ether defatting behind the extractum thin up, aqueous solution partly promptly obtains total Saponin with the water saturation n-butanol extracting liquid through evaporated under reduced pressure.
Described Radix Hedysari is the dry root of preface sweetvetch, and the main place of production is Gansu Province.From version in 1985 " Chinese pharmacopoeia begins, with Radix Hedysari single-row be a kind of Chinese medicine.20 world's the eighties are to the nineties studies show that the relevant chemical analysis of Radix Hedysari: contain bioactive substance in the Radix Hedysari, contain the antibiotic composition 1-3-hydroxyl-9 methoxyl group Lignum pterocarpi indici alkane (" northwest pharmaceutical journal " that the Radix Astragali does not have in the total Saponin of its main product, calendar year 2001, the 16th volume, 4 phases, 157 pages), provide the effect of discussion Radix Hedysari inherent material base.
Drug administration method of the present invention: oral or intravenous injection.
Major advantage of the present invention and effect:
Medicine of the present invention has tangible anti-myocarditis virus; suppress the pathogenic change effect of coxsackie B 3 viruses (being the main virus that causes the myocarditis morbidity) pair cell; compare with the Western medicine virazole; protective effect to the myocarditis mice is very obvious, and uses the dosage bigger five times than therapeutic dose also not see toxic and side effects.
Be animal (mouse core myositis model) experiment below: mice is divided into three groups at random, 20/group.First group is the myocarditis model group; Second group for using medication therapy groups of the present invention; The 3rd group is the normal control group.Therapeutic Method 4mg/, lumbar injection, once a day, model group and normal control group are used with the volume normal saline, and each group was observed 14 days continuously, tested triplicate.
Experiment shows, the Radix Hedysari extract has obvious reduction Coxsackie virus infection mortality of mice and sickness rate: the 10th day mortality rate 100% of infected group mice animal, and the mortality rate of treatment group is 35% (n=20 group), and the one-tenth live time of infective virus mice is obviously prolonged; From the myocarditis incidence, the Radix Hedysari extract has obvious reduction coxsackie B 3 virus infected mice myocarditis sickness rate, and the mouse cardiac muscle lesion degree is alleviated is that the total Saponin of Radix Hedysari can be treated mouse core myositis or be alleviated the cardiomyopathy degree.
In addition, have one group once to use the Western medicine virazole to experimentize, its result shows that medicine of the present invention obviously is better than virazole.
The specific embodiment
Further specify characteristics of the present invention below by embodiment.
Embodiment
This example is the method for the total Saponin of concrete preparation.Detailed process:
The Radix Hedysari rhizome is pulverized, and takes by weighing 800 grams, uses methanol merceration three times, and each 2000 milliliters, filter, merge methanol filtrate.Distilling under reduced pressure is reclaimed methanol and is got extractum.Extractum is used ether defatting three times, each 200 milliliters after adding 500 milliliters of dilutions of water.Aqueous solution is partly used the water saturation n-butanol extraction three times, each 500 milliliters.The n-butanol extracting liquid evaporated under reduced pressure promptly gets total Saponin 8.2 grams (buff powder), extraction ratio about 1%.Then total Saponin is mixed with oral liquid or injection.
Claims (1)
1. the application of the total Saponin of Radix Hedysari extract in preparation treatment myocarditis medicine is characterized in that the total Saponin of Radix Hedysari extract is mixed with oral liquid or intravenous injection liquid formulation with physiological saline solution or phosphate buffer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021252882A CN1177592C (en) | 2002-07-31 | 2002-07-31 | Myocarditis treating medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021252882A CN1177592C (en) | 2002-07-31 | 2002-07-31 | Myocarditis treating medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1389209A CN1389209A (en) | 2003-01-08 |
| CN1177592C true CN1177592C (en) | 2004-12-01 |
Family
ID=4745511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021252882A Expired - Fee Related CN1177592C (en) | 2002-07-31 | 2002-07-31 | Myocarditis treating medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1177592C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310650C (en) * | 2003-07-16 | 2007-04-18 | 中国科学院上海药物研究所 | Application of saponins in the preparing process of coxsackie virus resisting medicine |
-
2002
- 2002-07-31 CN CNB021252882A patent/CN1177592C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1389209A (en) | 2003-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| CN100500196C (en) | Method for preparing paris polyphylla total saponin | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN1140279C (en) | Blood-cleaning pill | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN1177592C (en) | Myocarditis treating medicine | |
| CN105687274B (en) | New application of acanthopanax giraldii harms wood heart or extract thereof | |
| CN103330781A (en) | Traditional Chinese medicine composite with anti-tumor effect and preparation method of injection of same | |
| WO2002089741A2 (en) | Compositions and methods for enhancing drug delivery | |
| CN1087275A (en) | Treatment ischemic brain, cardiovascular preparation Shumaining | |
| CN109432185B (en) | External traditional Chinese medicine composition for treating myofascitis and preparation method and application thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN113058013A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN111298075A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN107744552A (en) | It can strengthen muscles and bones, go silt detumescence, the composition of relaxing tendons and activating collaterals and preparation method and application | |
| CN106620380A (en) | Traditional Chinese medicine feed additive for preventing and treating viral diseases in livestock and poultry and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |